<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Genetic testing and CDx tools provider Personalis entered a partnership with genetic testing and bioinformatics company Tempus Labs to collaboratively commercialize Personalis' NeXT Personal Dx Minimal Residual Disease (MRD) assay, which enables personalized ctDNA panels of up to 1,800 variants with a resolution of around one part per million. The companies intend to initially focus on MRD testing in lung cancer.
      </p>
    </li>
    <li>
      <p>
        Under the partnership, Tempus is expected to integrate the tumor-informed, whole-genome liquid biopsy assay into its testing menu, market it to oncologists, and pay Personalis up to USD 12 million as milestone payments to fund the clinical testing.
      </p>
    </li>
    <li>
      <p>
        Personalis, on the other hand, would pay Tempus for the fair market value of sales, marketing, order requisition, and results delivery services and provide Tempus with warrants to buy up to ~9.2 million shares of Personalis' common stock over the next two years. Personalis would also receive, process, and bill any tests, manage reimbursement, and perform clinical validation tasks in breast cancer and immunotherapy monitoring.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.genomeweb.com/business-news/personalis-tempus-partner-commercialize-blood-based-minimal-residual-disease-test">
      Genome Web
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

PROMINENT_CATEGORY

<div>
 
 <p>Genetic testing and CDx tools provider Personalis has partnered with genetic testing and bioinformatics company Tempus Labs to commercialize Personalis' NeXT Personal Dx Minimal Residual Disease (MRD) assay. The assay allows for personalized ctDNA panels with high resolution. Initially, the focus will be on MRD testing in lung cancer.</p>
 <p>Under the partnership, Tempus will integrate the liquid biopsy assay into its testing menu, market it to oncologists, and pay Personalis milestone payments of up to USD 12 million for clinical testing. Personalis will compensate Tempus for sales, marketing, order requisition, and results delivery services. They will also provide warrants to buy shares and handle breast cancer and immunotherapy monitoring.</p>
 
</div>

Personalis collaborates with Tempus Labs to commercialize NeXT Personal Dx minimal residual disease assay

Personalis releases Q2 2023 earnings results; beats analysts’ estimates and reaffirms full-year 2023 guidance

Personalis releases Q1 2023 earnings results; affirms full-year 2023 guidance

Personalis partners with AstraZeneca for MRD testing

Personalis misses Q4 2022 analyst consensus; revenue dips and losses widen

Personalis partners with Moderna for upcoming clinical trial for cancer vaccine

Personalis beats analyst consensus; reports a dip in revenue and losses widen

Personalis reports dip in revenue for Q2 2022; beats analyst expectations

Personalis sues Foresight Diagnostics over patent infringement

Personalis reports dip in revenue for Q1 2022; misses analysts’ EPS expectations

All Updates